Fasting and Post-Glucose Load Measures of Insulin Resistance and Risk of Incident Atrial Fibrillation: The Cardiovascular Health Study

Existing literature in individuals without diabetes has not demonstrated a relationship between IR and incident AF; however, data are limited and only fasting glucose measures of IR were assessed. We evaluated the relationship of both fasting and post-glucose load IR measures with the development of atrial fibrillation in nondiabetic older adults.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research

Related Links:

AliveCor is close to our hearts. Literally. David Albert, the co-founder of the company, started experimenting with handheld, wireless ECG devices in the late 90s. Approximately 10 years later we tried out their FDA-cleared, medical grade gadget. It was a truly inspiring moment. Needless to say, we’ve been keeping track of their journey ever since. In our eyes Kardia is the textbook example of technology shaping health care, empowering and supporting not only e-patients, but medical professionals as well. So, let’s take a look at their newest creation, the KardiaMobile6L! Why did the chicken cross the ro...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Health Sensors & Trackers cardiology ecg fda Healthcare heart technology Source Type: blogs
AbstractAimsConcerns about the prognostic value of NYHA functional class (FC) in heart failure (HF) patients carrying a prophylactic implantable cardioverter defibrillator (ICD) are still present. We aimed to compare whether mortality and arrhythmic risk were different, in a cohort of HF patients undergoing ICD ‐only implant, according to their FC.Methods and resultsHF patients with left ventricle ejection fraction (LVEF) ≤35%, undergoing first prophylactic ICD‐only implant were collected from a multicentre nationwide registry (2006–2015). Six hundred and twenty‐one patients were identified (101 patients in ...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Short Communication Source Type: research
AimsImpact of type 2 diabetes mellitus (T2DM) on non ‐thromboembolic outcomes in atrial fibrillation (AF) is insufficiently explored. This prospective cohort study of AF patients aimed (i) to analyse the association between T2DM and heart failure (HF) events (including new‐onset HF), and all‐cause and cardiovascular mortality, (ii) to assess the impact of baseline T2DM treatment on outcomes, and (iii) to explore characteristics of new‐onset HF phenotypes in relation to T2DM status.Methods and resultsOf 1803 AF patients (515/1288, with/without prior HF), 389 (22%) had T2DM at baseline. After 5  years of media...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
Conditions:   Atrial Fibrillation;   Type 2 Diabetes Intervention:   Behavioral: High-intensity interval training + standard care Sponsor:   Ottawa Heart Institute Research Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Recent findings in atrial fibrillation (AF) patients receiving oral anticoagulation showed that diabetes without insulin therapy has a thromboembolic risk comparable to non-diabetic patients, whereas only diabetic patients on insulin have a heightened thromboembolic risk. We explored possible pathophysiological correlates of such finding on 90 AF patients on oral anticoagulation, divided according to diabetes status (N=30 without diabetes; N=29 with diabetes on oral antidiabetic drugs; N=31 with insulin-requiring diabetes).
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
AimDescribe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Methods and resultsKey background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed and compared with PARADIGM ‐HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Stu...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
ConclusionsIn patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF ‐related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
European Journal of Heart Failure, EarlyView.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Editorial Comment Source Type: research
AimDescribe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Methods and resultsKey background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed and compared with PARADIGM ‐HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Stu...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
ConclusionsIn patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF ‐related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Insulin | Nutrition | Study